Explore the latest advancements in global biosimilar access, including new treatments, strategic partnerships, and competitive market entries enhancing patient care.

Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to ...

AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular ...

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...

Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars ...

Biosimilar approvals surge in the US and Europe, enhancing access to denosumab and aflibercept therapies while driving significant health care savings.

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings. Patients with inflammatory bowel disease (IBD) who transitioned from ...

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market. The economic impact of biosimilars on the ...

Recent approvals and settlements enhance global access to aflibercept biosimilars, improving treatment options for age-related macular degeneration and diabetic retinopathy. Recent months have seen ...

After decades of filing citizen petitions, 6 publishing research papers, 7 and meeting with FDA decision makers, convincing US senators to introduce bills to amend the Biologics Price Competition and ...

The FDA has approved Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers and enhancing treatment options. The FDA has approved Bosaya ...